Active Substance Routes in Module 3.2.S: Full Data, CEP or ASMF

Section 3.2.S of the dossier can be filled in three different ways, and the route you choose determines who controls the data, who can answer deficiency questions and how easily you can change supplier later.

The three routes

The active substance information can be supplied in full within the application, through a Certificate of Suitability (CEP) issued by the EDQM, or by referring to an Active Substance Master File (ASMF). Each route carries the same scientific expectation, namely that the manufacture, characterisation and control of the substance are fully described. They differ in how that information reaches the assessor.

  • Full data in the dossier: everything sits in Module 3 and is visible to the applicant. This is common for new active substances and for manufacturers who are also the applicant.
  • CEP: the EDQM certifies that the substance is suitably controlled by the relevant Ph. Eur. monograph. The certificate is referenced in the dossier, and the applicant normally remains responsible for any additional controls not covered by the CEP.
  • ASMF: the master file is split into an applicant’s part and a restricted part. The applicant sees the first; the authority sees both.

What the applicant still owns

Using a CEP or an ASMF does not remove the applicant’s accountability for the finished product. The applicant must show that the active substance specification is appropriate for the product, that the supplier and manufacturing site are the ones named in the dossier, and that the information in the applicant’s part is consistent with what is actually delivered.

A recurring weakness is a mismatch between the supplier’s documents and the dossier, for example a different site, a changed specification or an outdated version of the master file. Assessors notice these inconsistencies quickly, and they generate avoidable questions.

Lifecycle and change management

The ASMF route in particular needs a working change-notification process. The holder must tell applicants about changes to the open part, and the applicants must assess whether a variation is needed on their own authorisations. Without a written agreement on who informs whom and by when, a supplier change can reach the authority before the marketing authorisation holder is even aware of it.

A second source of supply is easier to introduce if it is planned from the start. Qualifying an alternative CEP holder or ASMF holder early, with a comparison of impurity profiles and particle properties, avoids a rushed variation when supply becomes critical.

Practical checklist

  • Confirm the route per substance and per supplier, not per product.
  • Check that the CEP or ASMF version cited is current and covers the site in use.
  • Compare the supplier specification with your own and justify any differences.
  • Agree a technical or quality agreement covering change notification.
  • Keep the nitrosamine and other impurity risk assessments aligned with supplier information.

Questions to ask before filing

Does each active substance supplier in the dossier hold a current CEP or master file version that covers the exact site? Is there a written agreement on change notification? Do the impurity profiles of alternative suppliers match the one used in your clinical or bioequivalence batches? A short internal review of these questions before submission is far cheaper than answering them as deficiency questions, which can add months to a procedure and delay launch.

How PQRA helps

PQRA reviews the active substance documentation against the dossier, helps decide between the available routes, checks that CEP and ASMF references are consistent and current, and supports the variations that follow a supplier change.

Talk to us about your dossier: Contact PQRA

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *